OPC-21268 ANTAGONIZES ARGININE VASOPRESSIN-INDUCED VASOCONSTRICTOR RESPONSE IN THE SPINALLY-ANESTHETIZED DOG

被引：2

作者：

CHIHARA, T ^{[1
]}

NAKAMURA, S ^{[1
]}

ONOGAWA, T ^{[1
]}

YAMASHITA, T ^{[1
]}

YAMAMURA, Y ^{[1
]}

MORI, T ^{[1
]}

TOMINAGA, M ^{[1
]}

YABUUCHI, Y ^{[1
]}

机构：

[1] OTSUKA PHARMACEUT CO LTD,TOKUSHIMA INST NEW DRUG RES 2,TOKUSHIMA 77101,JAPAN

来源：

JAPANESE JOURNAL OF PHARMACOLOGY | 1995年 / 68卷 / 03期

关键词：

NONPEPTIDE VASOPRESSIN ANTAGONIST; VASCULAR ACTION; OPC-21268;

D O I：

10.1254/jjp.68.345

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

We studied the antagonistic actions of OPC-21268 (1-{1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl}-3,4-dihydro-2(1H)-quinolinone) on the arginine vasopressin (AVP)-induced vasoconstrictor response in the spinally-anesthetized dog. OPC-21268 at doses of 0.3, 1.0 and 3.0 mg/kg, i.v. produced a rightward parallel shift of the dose-response curves for AVP in a dose-dependent manner. The doses of OPC-21268 were similar to those that inhibited the AVP-induced vasoconstrictor response in the rat. This observation suggests that OPC-21268 acts as a V-1-AVP-receptor antagonist in peripheral resistance vessels in dogs as well as in rats.

引用

页码：345 / 347

页数：3

共 10 条

[1]

CHIBA S, 1992, EUR J PHARMACOL, V221, P393

[2] BLOCKING EFFECTS OF OPC-21268 AND OPC-31260 (VASOPRESSIN V1-RECEPTOR AND V2-RECEPTOR ANTAGONISTS) ON VASOPRESSIN-INDUCED CONSTRICTIONS IN ISOLATED, PERFUSED DOG FEMORAL ARTERIES [J].

CHIBA, S ;

TSUKADA, M .

JAPANESE JOURNAL OF PHARMACOLOGY, 1992, 59 (01) :133-135

[3] CLONING, FUNCTIONAL EXPRESSION AND TISSUE DISTRIBUTION OF HUMAN CDNA FOR THE VASCULAR-TYPE VASOPRESSIN RECEPTOR [J].

HIRASAWA, A ;

SHIBATA, K ;

KOTOSAI, K ;

TSUJIMOTO, G .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 203 (01) :72-79

[4] EFFECTS OF OPC-21268, AN ORALLY EFFECTIVE VASOPRESSIN V1 RECEPTOR ANTAGONIST IN HUMANS [J].

IMAIZUMI, T ;

HARADA, S ;

HIROOKA, Y ;

MASAKI, H ;

MOMOHARA, M ;

TAKESHITA, A .

HYPERTENSION, 1992, 20 (01) :54-58

[5] DISTINCT MECHANISMS OF ACTION OF V1 ANTAGONISTS OPC-21268 AND [D(CH2)5TYR(ME)AVP] IN MESANGIAL CELLS [J].

JAMIL, KMA ;

WATANABE, T ;

NAKAO, A ;

OKUDA, T ;

KUROKAWA, K .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 193 (02) :738-743

[6] HUMAN INTERNAL MAMMARY ARTERY RESPONSES TO NONPEPTIDE VASOPRESSIN ANTAGONISTS [J].

LIU, JJ ;

PHILLIPS, PA ;

BURRELL, LM ;

BURTON, BB ;

JOHNSTON, CI .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1994, 21 (02) :121-124

[7] EFFECT OF A NEW V1 ANTAGONIST (OPC-21268) ON VASCULAR ACTION OF VASOPRESSIN IN CULTURED RAT VASCULAR SMOOTH-MUSCLE CELLS [J].

OKADA, K ;

ISHIKAWA, S ;

SAITO, T .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 178 (02) :707-712

[8] THE MECHANISM UNDERLYING THE VASODILATOR ACTION OF BUNITROLOL - CONTRIBUTION OF ALPHA-1-ADRENOCEPTOR BLOCKING ACTION [J].

SATOH, K ;

NUNOKI, K ;

GOTO, T ;

TAIRA, N .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1985, 7 (03) :508-515

[9] ROLE OF VASOPRESSIN IN CARDIOVASCULAR REGULATION [J].

SHARE, L .

PHYSIOLOGICAL REVIEWS, 1988, 68 (04) :1248-1284

[10] OPC-21268, AN ORALLY EFFECTIVE, NONPEPTIDE VASOPRESSIN-VI RECEPTOR ANTAGONIST [J].

YAMAMURA, Y ;

OGAWA, H ;

CHIHARA, T ;

KONDO, K ;

ONOGAWA, T ;

NAKAMURA, S ;

MORI, T ;

TOMINAGA, M ;

YABUUCHI, Y .

SCIENCE, 1991, 252 (5005) :572-574

← 1 →